STING1 and cancer: Antitumor innate immune responses are in part regulated by TLRs, RIG-I–like receptors (RLRs), and the STING signaling pathway.56,73 Emerging data indicate that targeting TLRs, RLRs, and STING signaling may be a promising approach in the treatment of cancer, either alone or in combination with other immunotherapy agents.